



## **iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference**

August 8, 2017

**Gosselies, Belgium – August 8, 2017** – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that Michel Detheux, iTeos' Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 12:45 a.m. ET in New York, NY.

### **About iTeos Therapeutics SA**

iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A<sub>2A</sub>, immune checkpoints and non-immunogenic ("cold") tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos' competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information, please visit [www.iteosterapeutics.com](http://www.iteosterapeutics.com).

### **For further information, please contact:**

Michel Detheux, CEO

iTeos Therapeutics

+32 71 919 933

[michel.detheux@iteosterapeutics.com](mailto:michel.detheux@iteosterapeutics.com)

Sarah McCabe

Stern Investor Relations, Inc.

+ 1 212 362-1200

[sarah@sternir.com](mailto:sarah@sternir.com)

Amber Fennell, Mathew Neal, Hendrik Thys

Consilium Strategic Communications

+44 203 709 5700

[iteos@consilium-comms.com](mailto:iteos@consilium-comms.com)